IVD Studies Using Leftover Blood Samples Must Have Informed Consent - FDA
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of in vitro diagnostics will have to obtain informed consent from patients whose leftover blood samples are used in clinical trials or risk jeopardizing their regulatory submissions, according to FDA officials.